Femasys to strengthen its footprint in Europe by partnering with Kebomed

Image Credit: Femasys Inc.

Announcement

Femasys Inc., a known biomedical innovator making accessible fertility and non-surgical permanent birth control, and has been cost-effective to the women's community globally, has entered a partnership with Kebomed, a popular European medical device and equipment distributor, to marketize fembloc permanent birth control in Benelux and the French region, including Belgium, Luxembourg, and the Netherlands. France indicates a vast opportunity for the huge single market for FemBloc in Europe. Following this partnership will predominantly extend access to the only non-surgical permanent birth control option and mark a valuable milestone in Femasys’ European smart growth strategy alongside the CE approval.

This smart partnership strategy will work excellently with the expansion break to Femasys and for Europeans to explore the solution as a whole through Kebomed, a leading company. Furthermore, it will seize development and advancement globally in the European healthcare market.

Fembloc’s potency

The fembloc is the first non-surgical solution for permanent birth control, identifying a prominent need in women’s reproductive health. With the help of the patented delivery system, an exclusive blended polymer is placed into both fallopian tubes, safely degrades, and creates natural scar tissue permanently. Complementary to the surgical sterilization fembloc discards the risk of infection, recovery downtime, and anesthesia. This makes it even more accessible, safer, and cost-effective. There’s no other alternative yet in the market; FemBloc stands as an incomparable and competitively easy advancement with the vast global potential. The precise details of this solution are available on www.FemBloc.com.

Views and Statements from the company leader

Chief executive officer and founder of Femasys Inc., Kathy Lee-Sepsick, said, “We are excited to collaborate with kebomed, a popular distributor with excellent expertise in women’s health and brilliant market reach in main markets across Europe. France has been a large market opportunity for fembloc in the area, and kebomed’s developed gynecology-aimed and infrastructure portfolio makes them the perfect partner to leverage adoption, uncover important growth potential, and expand access.”

The chairman of Kebomed Europe AG, Soren Dalmark Kornerup, commented, “The fembloc marks a life-changing advancement in women’s health. With our strong presence in the developed European network reach and gynecology, we are best ranked in the scale of driving adoption in Benelux and France. With this permanent contraceptive solution, integration in our women’s health portfolio will strengthen our position and portfolio. It will also stimulate our leadership in this major field.”